Streptococcal toxic shock syndrome associated with necrotizing fasciitis.

Streptococcal toxic shock syndrome (strep TSS) with associated necrotizing fasciitis is a rapidly progressive process that kills 30-60% of patients in 72-96 h. Violaceous bullae, hypotension, fever, and evidence of organ failure are late clinical manifestations. Thus, the challenge to clinicians is to make an early diagnosis and to intervene with aggressive fluid replacement, emergent surgical debridement, and general supportive measures. Superantigens such as pyrogenic exotoxin A interact with monocytes and T lymphocytes in unique ways, resulting in T-cell proliferation and watershed production of monokines (e.g. tumor necrosis factor alpha, interleukin 1, interleukin 6), and lymphokines (e.g. tumor necrosis factor beta, interleukin 2, and gamma-interferon). Penicillin, though efficacious in mild Streptococcus pyogenes infection, is less effective in severe infections because of its short postantibiotic effect, inoculum effect, and reduced activity against stationary-phase organisms. Emerging treatments for strep TSS include clindamycin and intravenous gamma-globulin.

[1]  R. Kaul,et al.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Stevens The flesh-eating bacterium: what's next? , 1999, The Journal of infectious diseases.

[3]  A. Podbielski,et al.  A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties. , 1998, Research in microbiology.

[4]  A. Nather,et al.  Streptococcal necrotizing myositis: a rare entity. A report of two cases. , 1997, Clinical orthopaedics and related research.

[5]  A. M. Marciel,et al.  Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease , 1996, Infection and immunity.

[6]  J. Musser,et al.  Horizontal gene transfer among group A streptococci: implications for pathogenesis and epidemiology. , 1996, Trends in microbiology.

[7]  R. George,et al.  High-resolution genotyping elucidates the epidemiology of group A streptococcus outbreaks. , 1996, The Journal of infectious diseases.

[8]  D E Low,et al.  Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. , 1996, The New England journal of medicine.

[9]  D. Stevens,et al.  Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. , 1996, The Journal of infectious diseases.

[10]  D. Stevens,et al.  Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. , 1996, The Journal of infectious diseases.

[11]  T. File,et al.  Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D L Stevens,et al.  Streptococcal infections of skin and soft tissues. , 1996, The New England journal of medicine.

[13]  D. Stevens Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Stevens Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. , 1995, Emerging infectious diseases.

[15]  D. Stevens,et al.  Antibiotic effects on bacterial viability, toxin production, and host response. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Norrby-Teglund,et al.  Superantigenic properties of the group A streptococcal exotoxin SpeF (MF) , 1994, Infection and immunity.

[17]  J. Cavaillon,et al.  Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide , 1994, Infection and immunity.

[18]  A. Halstensen,et al.  Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features , 1994, The Lancet.

[19]  D. Stevens,et al.  Persistent acylation of high-molecular-weight penicillin-binding proteins by penicillin induces the postantibiotic effect in Streptococcus pyogenes. , 1994, The Journal of infectious diseases.

[20]  U. Andersson,et al.  Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B , 1994, Infection and immunity.

[21]  A. Halstensen,et al.  Necrotising fasciitis caused by group A streptococci in Western Norway , 1994 .

[22]  J. Musser,et al.  Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Musser,et al.  A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. , 1993, The Journal of clinical investigation.

[24]  D. Stevens,et al.  Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-beta synthesis. , 1993, The Journal of infectious diseases.

[25]  D. Stevens,et al.  The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. , 1993, FEMS microbiology letters.

[26]  S. Walmsley,et al.  Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  D. Stevens,et al.  Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. , 1993, The Journal of infectious diseases.

[28]  J. Cavaillon,et al.  Cytokine production by murine cells activated by erythrogenic toxin type A superantigen of Streptococcus pyogenes. , 1992, Immunobiology.

[29]  B. Schwartz,et al.  Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Dwight R. Johnson,et al.  Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. , 1992, The Journal of infectious diseases.

[31]  S. Holm,et al.  Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. , 1992, The Journal of infectious diseases.

[32]  S. Donta,et al.  Intravenous immunoglobulin therapy for toxic shock syndrome. , 1992, JAMA.

[33]  D. Stevens,et al.  Gram-positive shock , 1992 .

[34]  J. Karp Outbreak of group a streptococcus septicemia in children , 1992 .

[35]  D. Stevens,et al.  Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. , 1992, The Journal of infectious diseases.

[36]  A. Adimora,et al.  Outbreak of invasive group A streptococcal infections in a nursing home. Lessons on prevention and control. , 1992, Archives of internal medicine.

[37]  P. Schlievert,et al.  Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s , 1992, The Lancet.

[38]  E. Kaplan,et al.  Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates. , 1991, JAMA.

[39]  J. Musser,et al.  Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Köhler Streptococcal toxic shock syndrome. , 1990, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[41]  D. Musher,et al.  Spontaneous, nontraumatic gangrene due to Clostridium septicum. , 1990, Reviews of infectious diseases.

[42]  S. Waterman,et al.  Community-acquired group A streptococcal deaths in Los Angeles County. , 1989, The Journal of infectious diseases.

[43]  P. Schlievert,et al.  Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. , 1989, The New England journal of medicine.

[44]  M. Kotb,et al.  Cellular and biochemical responses of human T lymphocytes stimulated with streptococcal M proteins. , 1989, Journal of immunology.

[45]  P. Schlievert,et al.  Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production , 1989, Infection and immunity.

[46]  V. Winn,et al.  The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. , 1988, The Journal of infectious diseases.

[47]  V. Hříbalová Streptococcus pyogenes and the toxic shock syndrome. , 1988, Annals of internal medicine.

[48]  C. Hughes,et al.  Infection with Trichosporon pullulans. , 1988, Annals of internal medicine.

[49]  H. Knöll,et al.  Streptococcal outbreaks and erythrogenic toxin type A. , 1987, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology.

[50]  R. Khatib,et al.  Spontaneous gangrenous myositis induced by Streptococcus pyogenes: case report and review of the literature. , 1987, Reviews of infectious diseases.

[51]  D. Stevens,et al.  Effect of antibiotics on toxin production and viability of Clostridium perfringens , 1987, Antimicrobial Agents and Chemotherapy.

[52]  G. Rouan,et al.  Cryptogenic group A streptococcal bacteremia: experience at an urban general hospital and review of the literature. , 1986, Reviews of infectious diseases.

[53]  C. R. Weeks,et al.  Nucleotide sequence of the type A streptococcal exotoxin (erythrogenic toxin) gene from Streptococcus pyogenes bacteriophage T12 , 1986, Infection and immunity.

[54]  E. Kaplan,et al.  Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. , 1985, The Journal of pediatrics.

[55]  I. Brook Role of beta‐lactamase-producing bacteria in the failure of penicillin to eradicate Group A streptococci , 1985, Pediatric infectious disease.

[56]  J. Zabriskie,et al.  Rheumatic fever-associated B cell alloantigens as identified by monoclonal antibodies. , 1985, Arthritis and rheumatism.

[57]  G. Hallas The production of pyrogenic exotoxins by group A streptococci , 1985, Journal of Hygiene.

[58]  P. Peterson,et al.  Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. , 1981, The Journal of clinical investigation.

[59]  A. Gastañaduy,et al.  FAILURE OF PENICILLIN TO ERADICATE GROUP A STREPTOCOCCI DURING AN OUTBREAK OF PHARYNGITIS , 1980, The Lancet.

[60]  J. Feeley,et al.  Wound infections due to group A streptococcus traced to a vaginal carrier. , 1978, The Journal of infectious diseases.

[61]  E. Yunis,et al.  Association of HL-A 5 and immune responsiveness in vitro to streptococcal antigens , 1975, The Journal of experimental medicine.

[62]  R. Lancefield Current knowledge of type-specific M antigens of group A streptococci. , 1962, Journal of immunology.

[63]  H. Eagle Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. , 1952, The American journal of medicine.

[64]  F. Meleney HEMOLYTIC STREPTOCOCCUS GANGRENE , 1924 .

[65]  J. Musser,et al.  An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. , 1997, JAMA.

[66]  B. Schwartz,et al.  Selective Depletion Of Vβ-Bearing T Cells In Patients With Severe Invasive Group A Streptococcal Infections And Streptococcal Toxic Shock Syndrome , 1995 .

[67]  D. Stevens,et al.  Invasive group A streptococcal infection: New concepts in antibiotic treatment. , 1994, International journal of antimicrobial agents.

[68]  S. Holm,et al.  Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. , 1992, Scandinavian journal of infectious diseases.

[69]  D. Stevens Invasive group A streptococcus infections. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  E. Kaplan,et al.  Transmission of 'toxic strep' syndrome from an infected child to a firefighter during CPR. , 1991, Annals of emergency medicine.

[71]  Martin Pr,et al.  Streptococcal Serogroup: A Epidemic in Norway 1987–1988 , 1990 .

[72]  S. Svane Peracute spontaneous streptococcal myositis. A report on 2 fatal cases with review of literature. , 1971, Acta chirurgica Scandinavica.